Navigation Links
Ground Zero Pharmaceuticals Announces Expansion of Regulatory Consulting Services to South Africa

IRVINE, Calif., Oct. 9 /PRNewswire/ -- The advent of biosimilar drugs, new combinations of old ingredients and clinical trial failures in Phase 3 have required new emphasis on "doing it right, the first time." Better use of resources, carefully selected outsource partners and wise allocation of funding lead to fewer failed products in late stages and more success with the FDA review process.

In 2007 GZP added its first South African clients while dramatically increasing the number of Australian and US firms and programs that it represents to the FDA, for mid-discovery through full-scale clinical development and approval.

Several INDs that GZP created and submitted in 2006 received a first-cycle clearance to proceed with clinical trials. A number of pre-IND and end of Phase 2 meetings with the FDA led to successful acceleration of drug and biologic development programs for our clients. Special Protocol Assessments (SPAs) for Phase 3 programs have been submitted and successfully negotiated with the Agency, as well as Orphan Drug and Fast Track status requests. The firm is under contract for two electronic (eCTD) BLAs and three eCTD NDAs and expects additional such programs to be initiated in 2008.

According to Evan Siegel, Ph.D., President and Chief Executive Officer, "The additional resources, combined with zero turnover of our people, allow us to preserve continuity with our long-term clients and to offer the same level of expertise, commitment and rapid turnaround to our new clients. We continue to enjoy the privilege of working with new additions to drug and biologic pipelines while bringing our more than 400 aggregate years' experience in medical product development to bear on the programs of firms new to our partnership. We believe more than ever that bringing regulatory excellence to the table at the beginning of a program, combined with efficient and knowledgeable project management and technical expertise in all disciplines, can launch or re-launch a product into the FDA arena in a highly effective manner."

With GZP's wholly owned Australian subsidiary, Ground Zero Pharmaceuticals Pty Ltd. reaching its first anniversary, Dr. Sandra Webb, Executive Director, is optimistic about the growth in Australia stating, "More and more small biotech companies with early stage development products are realizing the value of collecting only necessary and sufficient data from the outset for timely discussions with the FDA at the key strategic points in their development plans."

In related developments, GZP has augmented its staff in the Regulatory, Project Management, and scientific areas to further improve its efficiency in handling the increased workload attendant to the growth of both its client base and new programs. Evan Siegel, Ph.D., President and Chief Executive Officer has been regularly lecturing as an Adjunct Professor at the University of Queensland in Brisbane, Australia and will be delivering several lectures at the University of Pretoria in South Africa this month. We expect that this will create new opportunities for client training in the coming years.

Therapeutic areas covered by GZP's services include cancers of both hard and soft tissues, AIDS, antiinfectives and antivirals, medical imaging, dermatological disorders such as psoriasis, acne, rosacea, erythema and herpes, anti-inflammatory/analgesics for rheumatoid arthritis, osteoarthritis and SLE, vaccines, coagulation disorders, wound healing, cardiovascular conditions, emergency plasma volume expansion, gastrointestinal disorders, hematological illness, and serious neurological disorders such as Stroke, Peripheral Arterial Occlusion, Parkinson's disease, and Alzheimer's disease.

Based in Irvine, a major center of biotechnology innovation in Southern California, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs and product development consulting firm providing strategic and tactical support to the pharmaceutical, biologics, biotechnology and medical device industries. Some of its service portfolio includes regulatory representation and submissions (paper and electronic), preclinical planning, clinical consulting, biostatistics, chemistry, manufacturing and controls consulting, and medical writing. The GZP core team is located internationally, throughout the US, Canada, Australia and Europe.

For further information please contact Ms. Tisha Templeton, Vice President of Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-419-6136, fax, +1-949-852-3655,

SOURCE Ground Zero Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Death Wishes Influenced By Ethnicity and Racial Background
3. Fresh Cases of Bird-Flu Prepares the Ground for More Chicken Martyrs
4. Seizure of Low Quantity of Heroin is No Ground for Bail: HC
5. Groundbreaking Asthma Intervention Lessons Help Inner-City Children
6. AIIMS Campus - A Breeding Ground for Mosquitoes
7. A slum in Mumbai – breeding ground for disease
8. Underground Water Contamination In Tripura
9. Adequate Ground Work before a Pandemic Necessary
10. Hospital infections gaining ground in Pennsylvania hospitals
11. Underground Air - Associated With - DNA Damages
Post Your Comments:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: